Early goal-directed care bundle,
does it really help with Improved functional recovery at six months?
research showsThe grade is C with 54 points. INTERACT3 included 3,221 bundle and 3,815 usual-care patients, 7,036 total at 121 hospitals, in its modified intention-to-treat population and analyzed 2,892 versus 3,363, 6,255 total, with a six-month modified Rankin Scale result. The common odds ratio for a worse functional outcome was 0.86 (95% CI 0.76 to 0.97), p=0.015. Cluster-level attrition and 11.1% missing patient outcomes were counted as two independent flaws.
ads claimThis is not the effect of one blood-pressure drug. It combines intensive blood-pressure lowering, hyperglycemia correction, fever treatment, and reversal of abnormal anticoagulation within hours. It cannot be marketed as proof for any single component alone.
Useful facts when choosing a product
- Hospitals crossed from usual care to the bundle in a stepped-wedge cluster design.
- Researchers masked to assignment assessed six-month function.
- NCT03209258 and ChiCTR-IOC-17011787 register the same trial.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.interact3-early-goal-directed-care-bundle.UNK.functional-recovery-at.improve.usual-careUnknown > INTERACT3 early goal-directed care bundle > Unknown > functional recovery at > Improvement claim > Usual care
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
The trial randomized the transition order of 144 hospitals in ten countries. Twenty-two withdrew before enrollment, and one was excluded for a regulatory problem with its enrolled-patient data deleted, leaving 121 hospitals. This was counted as the first avoidable flaw: cluster-level attrition. The modified intention-to-treat population comprised 3,221 bundle and 3,815 usual-care patients, 7,036 total; only 2,892 versus 3,363, 6,255 total, had a six-month Rankin result for primary analysis, leaving 11.1% missing outcomes. This was counted as a second avoidable flaw independent of cluster attrition. The primary common odds ratio for a worse functional outcome was 0.86 (95% CI 0.76 to 0.97), p=0.015. Multiple-imputation and country-and-patient-adjusted sensitivity analysis remained significant, OR 0.84 (0.73 to 0.97). NCT03209258 and ChiCTR-IOC-17011787 are dual registrations of the same INTERACT3 trial. Public and nonprofit funding was mixed with support from Sichuan Credit Pharmaceutic and Takeda China.
Why this is classified as C (54)
The prespecified six-month functional endpoint, which includes death, improved in one large international trial. Cluster-level attrition including data deletion and 11.1% missing patient outcomes were counted as two independent flaws, giving C with 54 points.
Counterpoint. Targets and correction speed require clinician adjustment for imaging, onset time, baseline pressure, anticoagulant type, and comorbidity.
Rejudgment record. Cross-check applied — Cross-checked the Lancet report, protocol, NCT03209258, and ChiCTR registration for the death-inclusive primary endpoint, hospital and patient counts, masked assessment, cluster attrition including data deletion, 11.1% missing patient outcomes, sensitivity analyses, and mixed funding
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved full six-month functional distribution | C | The common odds ratio was 0.86 (0.76 to 0.97). |
| Reduced dichotomized death or disability at six months | D | The OR was 0.89 (0.78 to 1.02), not statistically significant. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Ma L, Hu X, Song L, Chen X, Ouyang M, Billot L, Li Q, Malavera A, Li X, Muñoz-Venturelli P, de Silva A, Thang NH, Wahab KW, Pandian JD, Wasay M, Pontes-Neto OM, Abanto C, Arauz A, Shi H, Tang G, Zhu S, She X, Liu L, Sakamoto Y, You S, Han Q, Crutzen B, Cheung E, Li Y, Wang X, Chen C, Liu F, Zhao Y, Li H, Liu Y, Jiang Y, Chen L, Wu B, Liu M, Xu J, You C, Anderson CS, INTERACT3 Investigators. 2023 | International stepped-wedge cluster-randomized trial with masked outcome assessment | 144 hospitals randomized; 22 withdrew before recruitment and one was excluded for a regulatory problem with enrolled data deleted; modified intention-to-treat 3,221 versus 3,815 at 121 hospitals; six-month primary analysis 2,892 versus 3,363 | Public and nonprofit funding from the UK Joint Global Health Trials scheme, Wellcome, West China Hospital, and Australian NHMRC, mixed with Sichuan Credit Pharmaceutic and Takeda China | Functional recovery across the full modified Rankin Scale distribution at six months | Common odds ratio for a worse functional outcome 0.86 (95% CI 0.76 to 0.97), p=0.015; adjusted sensitivity OR 0.84 (0.73 to 0.97) | Single large patient-centered outcome trial |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-15).
Final verification and publication gate: Codex · Evidence date: 2026-08-15 · Corrections: none
Cite this verdict
[Chamgap] Early goal-directed care bundle x functional recovery after acute intracerebral hemorrhage — Evidence Grade C·54. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/cognition/interact3-goal-directed-care-bundle-intracerebral-hemorrhage-functional-recovery/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.